Cedna

Cedna is an emerging biotechnology company focused on the development of advanced liquid biopsy technologies for early cancer detection and monitoring. The company leverages a proprietary platform designed to enhance the sensitivity and specificity of circulating tumor DNA (ctDNA) analysis, aiming to overcome current limitations in non-invasive diagnostic testing. By providing high-resolution genomic insights from simple blood draws, Cedna seeks to enable personalized treatment strategies and improve patient outcomes across various oncological indications. The company is currently advancing its technology through early-stage validation and strategic research initiatives.